Allergan Aesthetics wins second FDA indication for SKINVIVE
Share
- Allergan Aesthetics received U.S. FDA approval for its SKINVIVE hyaluronic acid injectable to improve horizontal neck lines.
- The parent company shares moved down to $221.59 following the regulatory announcement.
- The approval represents the second clinical indication for the product line to drive aesthetic segment growth.
Allergan Aesthetics (NYSE:ABBV) received U.S. FDA approval for SKINVIVE neck treatments as its second product indication.
This new regulatory clearance expands the treatment line beyond its original approval for cheek skin smoothness.
The treatment is the first and only hyaluronic acid injectable approved by the agency for this specific area.
Clinical data demonstrated that optimal administration of the treatment produced visible improvements lasting up to six months.
The company stated that the product maintained a mostly mild and transient safety profile during trials.
This approval forms part of a broader corporate strategy to expand the JUVÉDERM collection across multiple demographics.
